Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ROCKY MOUNTAIN CLINICS LLC

NPI: 1598478059 · FORT COLLINS, CO 80525 · Clinical Pathology/Laboratory Medicine Physician · NPI assigned 12/29/2022

Billing Flags · Automated signals — not evidence of fraud
Single-Code Concentration

99% of spending on code G0483 with only 2 total codes billed. Highly concentrated billing profile.

$13.08M
Total Medicaid Paid
77,557
Total Claims
49,148
Beneficiaries
2
Codes Billed
2022-12
First Month
2024-12
Last Month

Provider Details

Authorized OfficialMALOUFF, PATRICIA (FACILITIES DIRECTOR)
NPI Enumeration Date12/29/2022

Related Entities

Other providers sharing the same authorized official: MALOUFF, PATRICIA

ProviderCityStateTotal Paid
ROCKY MOUNTAIN CLINICS LLC LAKEWOOD CO $243K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2022 1,304 $224K
2023 37,261 $6.30M
2024 38,992 $6.55M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 76,476 48,309 $12.97M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,081 839 $107K